HMG －CoA 还原酶抑制剂对腹膜透析患者腹膜纤维化的影响

摘要

Objective To research on the effect of atorvastatin on the Peritoneal fibrosis by detecting the IL -6、CA125 of Di-alysate with enzyme -labeled immunosorbent assay(ELISA).Method Fifty patients were divided into two groups to receive ator-vastatin 20 mg daily or Placebo for three months,then stop taking the medication for one month,And then cross taking these two drugs three months.Results The level of the CA125 in patients was improved by atorvastatin,the level of the IL -6 was declined (P <0.05).Conclusion The peritoneal fibrosis of the peritoneal dialysis patients is improved by atorvastatin.%目的：通过酶联免疫吸附方法（ELISA）检测腹透液中白细胞介素－6（IL －6）、糖类抗原125（CA125）的水平，观察他汀类药物对腹膜透析（PD）患者腹膜纤维化的抑制作用。方法：采用随机对照研究，将50例 PD 患者随机分为阿托伐他汀（20 mg／d）组和安慰剂组，治疗3个月，停用1个月后，交换处理3个月，留取每次治疗前后腹透液标本及每月留取腹透液标本，观察腹透液中 IL －6、CA125的变化情况。结果：阿托伐他汀组治疗后腹透液中 IL －6水平较安慰剂组有明显下降，而 CA125水平则有明显升高，差异有统计学意义（P ＜0.05），阿托伐他汀组治疗前后及治疗过程中， CA125呈逐步上升趋势，IL －6水平呈逐步下降趋势，而安慰剂组治疗前后及治疗过程中炎性反应因子变化不明显。结论：阿托伐他汀对腹膜纤维化有一定的拮抗作用。